Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 101, Issue 3, 2006, Pages 390-397

  Secord, Angeles Alvarez ^a   Lee, Paula S ^a   Darcy, Kathleen M ^b   Havrilesky, Laura J ^a   Grace, Lisa A ^a   Marks, Jeffrey R ^c   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Biomarker; MASPIN; Ovarian carcinoma; Prognosis

Indexed keywords

BETA ACTIN; CARBOPLATIN; CISPLATIN; MASPIN; PACLITAXEL;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER STAGING; CELL LYSATE; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; FROZEN SECTION; GROUPS BY AGE; GYNECOLOGY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; ONCOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ACTINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS, PHASE II; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; FROZEN SECTIONS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOBLOTTING; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SERPINS; TREATMENT OUTCOME;

EID: 33646718965     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.02.014     Document Type: Article

References (51)

1. Zou Z., Anisowicz A., Hendrix M.J.C., et al. MASPIN, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
2. Hopkins C.R., and Whisstock J. Function of MASPIN. Science 265 (1994) 1893-1894
3. Sheng S., Carey J., Seftor E.A., Dias L., Hendrix M.J.C., and Sager R. MASPIN acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11669-11674
4. Seftor R.E.B., Seftor E.A., Sheng S., Pemberton P.A., Sager R., and Hendrix M.J.C. MASPIN suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58 (1998) 5681-5685
5. Maass N., Hojo T., Zhang M., Sager R., Jonat W., and Nagasaki K. Maspin-A novel protease inhibitor with tumor suppressing activity in breast cancer. Acta Oncol. 39 8 (2000) 931-934
6. Zhang M., Volpert O., Shi Y.H., and Bouck N. MASPIN is an angiogenic inhibitor. Nature 6 2 (2000) 196-199
7. Friedrich M.G., Toma M.I., Petri S., et al. Expression of maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Eur. Urology 45 6 (2004) 737-743
8. Hojo T., Akiyama Y., Nagasaki K., et al. Association of maspin expression with malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett. 171 (2001) 103-110
9. Maass N., Hojo T., Rosel F., Ikeda T., Jonat W., and Nagasaki K. Down regulation of the tumor suppressor gene MASPIN in breast carcinoma is associated with a higher risk of distant metastasis. Clin. Biochem. 34 (2001) 303-307
10. Machtens S., Serth J., Bokemeyer C., et al. Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int. J. Cancer 95 (2001) 337-342
11. Umekita Y., Ohi Y., Sagara Y., and Yoshida H. Expression of MASPIN predicts poor prognosis in breast cancer patients. Int. J. Cancer 100 (2002) 452-455
12. Sood A.K., Fletcher M.S., Gruman L.M., et al. The paradoxical expression of MASPIN in ovarian carcinoma. Clin. Cancer Res. 8 (2002) 2923-2932
13. Song S.Y., Lee S.K., Kim D.H., et al. Expression of MASPIN in colon cancers: its relationship with p53 expression and microvessel density. Dig. Dis. Sci. 47 (2002) 1831-1835
14. Ito R., Nakayama H., Yoshida K., Oda N., and Yasui W. Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncol. Rep. 12 (2004) 985-990
15. Boltze C. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol. Res. Pract. 200 11-12 (2005) 783-790
16. Terashima M., Maesawa C., Oyama K., et al. Gene expression profiles in human gastric cancer: expression of maspin correlates with lymph node metastasis. Br. J. Cancer 92 (2005) 1130-1136
17. Zhang M., Magit D., and Sager R. Expression of maspin in prostate cells is regulated by a positive Ets element and a negative hormonal response element recognized by androgen receptor. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5673-5678
18. Zhang M., Maass N., Magit D., and Sager R. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ. 8 (1997) 179-186
19. Domann F.E., Rice J.C., Hendrix M.J.C., and Futscher B.W. Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer 85 (2000) 805-810
20. Hendrix M.J.C. De-mystifying the mechanism (s) of maspin. Nat. Med. 6 4 (2000) 374-376
21. Zou Z., Gao C., Nagaich A.K., et al. p53 regulates the expression of the tumor suppressor gene maspin. J. Biol. Chem. 275 9 (2000) 6051-6054
22. Costello J.F., and Vertino P.M. Methylation matters: a new spin on maspin. Nat. Genet. 31 (2002) 123-124
23. Widschwendter M., and Jones P. DNA methylation and breast carcinogenesis. Oncogene 21 (2002) 5462-5482
24. Feldman R.J., Sementchenko V.I., Gayed M., Fraig M.M., and Watson D.K. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res. 63 (2003) 4626-4631
25. Fitzgerald M., Oshiro M., Holtan N., et al. Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia 5 5 (2003) 427-436
26. Oshiro M.M., Watts G.S., Wozniak R.J., et al. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 22 (2003) 3624-3634
27. Futscher B.W., O'Meara M.M., Kim C.J., et al. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 6 4 (2004) 380-389
28. Kim S., Han J., Kim J., and Park C. Maspin expression is transactivated by p63 and is critical for modulation of lung cancer progression. Cancer Res. 64 (2004) 6900-6905
29. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the GOG, SWOG, and ECOG. J. Clin. Oncol. 19 4 (2001) 1001-1007
30. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 18 1 (2000) 106-115
31. Havrilesky L.J., Alavarez A.A., Whitaker R.S., Marks J.R., and Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol. Oncol. 83 (2001) 491-500
32. Mehta C.R., and Patel N.R. A network algorithm for performing Fisher's exact test in r × c contingency tables. J. Am. Stat. Assoc. 78 (1983) 427-434
33. Pemberton P.A., Tipton A.R., Pavloff N., et al. Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J. Histochem. Cytochem. 45 (1997) 1697-1706
34. Hirai K., Koizumi K., Haraguchi S., et al. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann. Thorac. Surg. 79 1 (2005) 248-253
35. Marioni G., Blandamura S., Giacomelli L., et al. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46 5 (2005) 576-582
36. Boltze C., Schneider-Stock R., Quednow C., et al. Proteome analysis identified maspin as a special feature of papillary thyroid carcinoma. Int. J. Oncol. 23 5 (2003) 1323-1328
37. Mohsin S.K., Zhang M., Clark G.M., et al. Maspin expression in invasive breast cancer: association with other prognostic factors. J. Pathol. 199 4 (2003) 432-435
38. Smith S.L., Watson S.G., Ratschiller D., et al. Maspin-The most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer-Is strongly expressed in preneoplastic bronchial lesions. Oncogene 22 54 (2003) 8677-8687
39. Boltze C., Schneider-Stock R., Meyer F., et al. Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol. Rep. 10 6 (2003) 1783-1787
40. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61 (1983) 413-420
41. Vogl S.E., Pagano M., Kaplan B.H., Greenwald E., Arseneau J., and Bennett B. Cisplatin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. Cancer 51 (1983) 2024-2030
42. Delgado G., Oram D.H., and Petrilli E.S. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol. Oncol. 18 (1984) 293-298
43. Pohl R., Dallenbach-Hellweg G., Plugge T., and Czernobilsky B. Prognostic parameters in patients with advanced ovarian malignant tumors. Eur. J. Gynaecol. Oncol. 5 (1984) 160-169
44. Redman J.R., Petroni G.R., Saigo P.E., Geller N.L., and Hakes T.B. Prognostic factors in advanced ovarian carcinoma. J. Clin. Oncol. 4 (1986) 515-523
45. Hainsworth J.D., Grosh W.W., Burnett L.S., Jones H.W., Wolff S.N., and Greco F.A. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann. Intern. Med. 108 (1988) 165-170
46. Sutton G.P., Stehman F.B., Einhorn L.H., Roth L.M., Blessing J.A., and Ehrlich C.E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J. Clin. Oncol. 7 (1989) 223-229
47. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979
48. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72 3 (1999) 278-287
49. Bristow R.E., and Montz F.J. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol. Oncol. 83 1 (2001) 39-48
50. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 2 (1998) 103-108
51. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., and Enrich L.J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6 (1988) 983-989